MRK

Merck & Co., Inc. - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Merck & Co., Inc. operates through two primary segments: Pharmaceutical (human health pharmaceuticals and vaccines) and Animal Health. The company is a large accelerated filer incorporated in New Jersey. As of April 30, 2025, there were approximately 2.51 billion shares of common stock outstanding.

Key Financial Metrics

Note: Free Cash Flow calculated as Operating Cash Flow less Capital Expenditures ($1,328 million).

Material Changes vs. Prior Period

• Sales: Decreased 2% to $15.5 billion. The decline was driven by lower vaccine sales (primarily Gardasil/Gardasil 9 due to paused shipments to China) and virology (Lagevrio), partially offset by growth in oncology (Keytruda), cardiovascular (Winrevair), and diabetes (Januvia).
• Profitability: Net income increased 7% to $5.1 billion despite lower sales, driven by a lower effective tax rate (13.9% vs. 15.9%) and reduced restructuring costs ($69 million vs. $123 million).
• Research & Development: Expenses decreased 9% to $3.6 billion. This decline is largely attributable to the absence of the $656 million charge recorded in Q1 2024 for the Harpoon Therapeutics acquisition.
• Segment Performance: Pharmaceutical segment sales declined 3% to $13.6 billion. Animal Health segment sales grew 5% to $1.6 billion.
• Geographic Mix: U.S. sales grew 14% to $8.5 billion, while International sales declined 16% to $7.0 billion, heavily impacted by the China vaccine situation.

Guidance, Outlook, and Risks

• Business Development: Merck entered an exclusive license agreement with Hengrui Pharma for HRS-5346 (Lipoprotein(a) inhibitor), expecting a $200 million R&D charge in Q2 2025. The company also acquired a WuXi Vaccines facility in Ireland for $437 million.
• Regulatory & Pricing Risks:
  • IRA Impact: Januvia is subject to government price negotiation effective Jan 1, 2026. Janumet and Janumet XR are included for price setting effective Jan 1, 2027.
  • Tariffs: Management anticipates approximately $200 million in additional expenses in 2025 due to tariffs, primarily related to imports into China.
  • Patent Expirations: Key U.S. exclusivity for Januvia/Janumet is expected to end in May 2026, and Janumet XR in July 2026, following favorable court rulings on salt/polymorph patents.
• Legal Contingencies:
  • IRS Examination: Received Notices of Proposed Adjustment (NOPAs) regarding the 2017/2018 transition tax, proposing an increase of ~$1.3 billion plus $260 million in penalties. Merck intends to vigorously contest this.
  • Product Liability: Approximately 500 cases pending regarding Dr. Scholl's foot powder and 245 cases regarding Gardasil/Gardasil 9. Merck recently won summary judgment in 16 Gardasil bellwether cases.
  • Capital Allocation: The company repurchased $1.2 billion of stock in Q1 2025. A new $10 billion share repurchase authorization was approved in January 2025, leaving $11.2 billion remaining as of March 31, 2025.

  Investor Verification Checklist

  • China Vaccine Exposure: Verify the duration of the shipment pause to China for Gardasil/Gardasil 9 and the impact on 2025 full-year vaccine revenue guidance.
  • IRS Dispute: Monitor the status of the $1.56 billion (tax + penalties) IRS proposed adjustment and the likelihood of a material charge if the appeal fails.
  • Keytruda Growth: Assess the sustainability of Keytruda's 4% growth given the negative pricing impact of new EU indications and potential biosimilar competition timelines.
  • Januvia Pricing: Confirm the net pricing impact of the Medicaid rebate cap elimination and the upcoming IRA price negotiation in 2026.
  • R&D Pipeline: Track the FDA review status of subcutaneous Keytruda (PDUFA date Sept 2025) and patritumab deruxtecan (following a CRL in June 2024).